Related Experiment Video
Updated: Sep 14, 2025
03:30
Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
Published on: October 25, 2024
1.7K
Medium- to Long-Term Follow-Up Study on Modified Manchester Procedure for Pelvic Organ Prolapse
Yan Chen1, Shuqiong Xu2, Na Luo1
1Department of Women's Health, Dali Bai Autonomous Prefecture Maternal and Child Health Care Hospital, Dali, 671000, Yunnan Province, China.
International Urogynecology Journal
|July 23, 2025
Summary
The modified Manchester procedure for pelvic organ prolapse demonstrates good safety and efficacy. This surgical approach shows a low rate of severe complications and satisfactory long-term outcomes for patients.
Area of Science:
- Gynecology
- Urogynecology
- Surgical Procedures
Background:
- Pelvic organ prolapse (POP) affects many women, impacting quality of life.
- Surgical interventions are common for POP treatment.
- The modified Manchester procedure is one such surgical option.
Purpose of the Study:
- To evaluate the complications associated with the modified Manchester procedure.
- To assess the medium- to long-term therapeutic outcomes of this procedure.
- To determine the safety and efficacy of the modified Manchester procedure for POP.
Main Methods:
- Retrospective analysis of clinical data from 254 patients.
- Data collected from July 2015 to May 2023.
- Evaluation of perioperative status and medium- to long-term follow-up results.
Main Results:
- No intraoperative injuries or major complications like hemorrhage were reported.
- Perioperative issues included urinary retention (7.5%), fever (5.1%), and UTIs (1.2%).
- With a median follow-up of 4.18 years, 9.25% experienced subjective recurrence, with low rates of surgical failure, de novo SUI, and dysuria. Patient satisfaction was high (94.8%).
Conclusions:
- The modified Manchester procedure is a safe and effective treatment for pelvic organ prolapse.
- It is associated with a low incidence of severe complications.
- The procedure offers satisfactory medium- to long-term therapeutic outcomes for patients.
